Genomma Sets New Pricing Sights

Genomma Sets New Pricing Sights


Genomma Lab is targeting mid-week to retry a sale of up to MXP2bn ($154m) in what would be the Mexican pharmaceutical and hygiene products company’s domestic bond debut, according to people following the sale. It plans a 10-year fixed-rate note sale

Already have an account?

Free trial

Take a free two-week trial now for the latest news, data and market analysis.

Free Trial